-
Earth Color Inc
Distance: 0.0 Mi527 W 34th St Fl 4
10001 New York -
Manhattan Pharmaceuticals, Inc.
Distance: 0.0 Mi787 7th Ave Fl 48
10019 New York -
Bright Rewards
Distance: 0.0 Mi16 E 40th St Fl 6
10016 New York -
CRM Media, LLC
Distance: 0.0 Mi494 8th Ave 8th Fl
10001-2509 New York -
ITS Worldwide LLC
Distance: 0.0 Mi142 W 36th St Fl 2
10018-8807 New York
Website Links
Description
The rapid incursion of pharmaceutical industry influence into sex research and professional education in the 1990s provoked our "New View" campaign in 2000. Our goal is to expose the deceptions and consequences of industry involvement in sex research, professional sex education, and sexual treatments, and to generate conceptual and practical alternatives to the prevailing medical model of sexuality. The centerpiece of the campaign is the "new view" document which is on the MANIFESTO page of this website. In summer, 2000, Leonore Tiefer, Ph.D. convened a group of feminist social scientists and clinicians who wrote the manifesto and planned an academic and public campaign to follow it up. Many of the pieces on our PRESS page are the result of our publicity efforts. Many people signed on to our campaign as ENDORSERS , and we welcome new endorsers at any time. Our first CONFERENCE occurred in San Francisco on March 9, 2002. It featured Thomas Bodenheimer, MD, Carol Tavris, PhD and Judy Norsigian (of Ourbodies, Ourselves), and was an intellectual, political and networking success. Our first BOOK , titled "A New View of Women's Sexual Problems," edited by Ellyn Kaschak and Leonore Tiefer, was published on March 1, 2002. In 2003, we put together a TEACHING MANUAL for the New View. It contains 12 classroom and workshop activities that allow participants to think about women's sexual problems in a variety of ways. The Manifesto is also reprinted as are some press pieces. One of our major activities has been to monitor the drug industry's activities as regards new drugs for women's sexuality. On December 2, 2004, members of the New View Campaign participated in a historic hearing of the FDA